Cancer immunotherapy is any treatment that uses our own immune system to fight cancer. There are several types of immunotherapy, some of which are already being used routinely, and others still mostly experimental. They are generally a second line of treatment, following chemotherapy, radiotherapy or surgery. 

The new programme aims to increase the detection of MPM, focusing on workers at asbestos cement factories, in Portugal, who have been exposed to asbestos since the 1960’s, and covering a total of around 200 people who have already been identified by SOS Amianto.
 

Through the provision of these two-year collaborative research grants, the Chan Zuckerberg Initiative (CZI) programme aims to accelerate cutting-edge research and technology in metabolism and metabolic physiology. The objective of these grants is to map, measure, and integrate metabolism across different scales—from molecules and organelles to cells and tissues—deepening our understanding of human biology, and to investigate the metabolic processes that maintain physiological homeostasis.

The Champalimaud Foundation, a private non-profit research institution located in Lisbon, Portugal, has achieved a significant milestone in cancer research and pre-clinical development by obtaining exclusive rights to deploy synthetic biology technologies initially licensed from Stanford University and further developed by Refuge Biotechnologies (Refuge), a pioneering synthetic biology company specialising in cancer immunotherapy.

A novel infrastructure for storing, consulting and analysing medical data will be presented at the Open Day of the Champalimaud Foundation (FC) Breast Unit, which is taking place today, October 16. It was created by the Unit's Digital Surgery Lab, a multidisciplinary team led by surgeon Pedro Gouveia, in partnership with the telecommunications company Altice and the Portuguese company BMD Software.